十三烷基磺酸钠 | 5802-89-1

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸盐/亚磺酸盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 十三烷基磺酸钠
• 中文别名: 正十三烷磺酸钠；正十三烷基硫酸钠
• 英文名称: tridecyl sulfonic acid sodium salt
• 英文别名: sodium dodecylsulfonate；sodium tridecanesulfonate；tridecane-1-sulfonic acid ; sodium-salt；Tridecan-1-sulfonsaeure; Natrium-Salz；1-Tridecanesulfonic Acid Sodium Salt；sodium;tridecane-1-sulfonate
• CAS: 5802-89-1
• 化学式: C₁₃H₂₇O₃S*Na
• 分子量: 286.411
• InChiKey: CACJZDMMUHMEBN-UHFFFAOYSA-M

物化性质

• 熔点：
  185-189°C
• 稳定性/保质期：

  在常温常压下保持稳定

计算性质

• 辛醇/水分配系数(LogP)：
  0.85
• 重原子数：
  18
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2904100000

文献信息

• Thermoplastic resin composition and elastomer composition
  申请人：——

  公开号：US20040106732A1

  公开（公告）日：2004-06-03

  Provided are a thermoplastic resin composition which is excellent in oil resistance, heat resistance, weatherability, impact resistance, transparency, and moldability, and which can be produced economically, an elastomer composition with low hardness and high tensile strength which is excellent in oil resistance and compression set, and a molded object produced by molding the thermoplastic resin composition or elastomer composition. The composition is produced by compounding a thermoplastic resin or an elastomer with a block copolymer having at least one methacrylic ester polymer block and at least one acrylic ester polymer block. Also provided are a process for producing a methacrylic ester-acrylic ester-methacrylic ester block copolymer which requires hardly any purification, which is excellent in heat resistance and weatherability, and in which the molecular weight and the molecular-weight distribution are controlled, and a methacrylic ester-acrylic ester-methacrylic ester block copolymer produced by the process.

  提供了一种热塑性树脂组合物，具有优异的耐油性、耐热性、耐候性、抗冲击性、透明度和成型性，且可经济生产；一种低硬度、高拉伸强度的弹性体组合物，具有优异的耐油性和压缩回弹性；以及由该热塑性树脂组合物或弹性体组合物成型而成的成型物。该组合物通过将热塑性树脂或弹性体与至少具有一个甲基丙烯酸酯聚合物块和至少一个丙烯酸酯聚合物块的嵌段共聚物混合制备而成。 同时提供了一种制备甲基丙烯酸酯-丙烯酸酯-甲基丙烯酸酯嵌段共聚物的方法，该方法几乎不需要纯化，具有优异的耐热性和耐候性，并且分子量和分子量分布可控；以及由该方法制备的甲基丙烯酸酯-丙烯酸酯-甲基丙烯酸酯嵌段共聚物。
• Process for recovering refractile bodies containing heterologous proteins from microbial hosts and the use thereof
  申请人：CETUS ONCOLOGY CORPORATION

  公开号：EP0206828A2

  公开（公告）日：1986-12-30

  A refractile material containing a heterologous protein is recovered from a host microorganism cell culture transformed to produce the protein. One recovery process involves disrupting the cell wall and membrane of the host cell, removing greater than 99% by weight of the salts from the disruptate, redisrupting the desalted disruptate, adding a material to the disruptate to create a density or viscosity gradient in the liquid within the disruptate, and separating the refractile material from the cellular debris by high-speed centrifugation (Figure 1 Another version of such a recovery process comprises the further steps of solubilizing the refractile material under reducing conditions, organically extracting the solubilized refractile material, and isolating said refractile material from the extractant (Figure 2). Preferably the protein is recombinant IL-2 or IFN-β and the salt removal step is carried out by diafiltration.

  含有异源蛋白质的折射材料是从转化产生蛋白质的宿主微生物细胞培养物中回收的。一种回收工艺包括破坏宿主细胞的细胞壁和细胞膜，从破坏物中除去超过 99% （按重量计）的盐分，重新破坏脱盐的破坏物，向破坏物中添加一种材料，以在破坏物中的液体中形成密度或粘度梯度、通过高速离心将折射物质从细胞碎片中分离出来（图 1）。 这种回收工艺的另一个版本包括以下步骤：在还原条件下增溶折射物质，有机萃取增溶的折射物质，从萃取剂中分离出所述折射物质（图 2）。 蛋白质最好是重组 IL-2 或 IFN-β，除盐步骤通过重滤进行。
• Stable formulation of biologically active proteins for parenteral injection
  申请人：CETUS CORPORATION

  公开号：EP0217645A2

  公开（公告）日：1987-04-08

  A pharmaceutical composition containing IL-2 or IFN-β dissolved in a suitable carrier medium at pH 7.0 to 8.0 stabilized with sodium laurate is suitable for parenteral injection into humans or animals. This formulation may be prepared by adding to either protein, after its recovery from a transformed organism, an effective amount of sodium laurate at a pH of 9 to 9.5 and then adjusting the pH of the formulation to between 7.0 and 8.0. The invention thus provides the use of sodium laurate in stabilizing an interleukin-2 or interferon-β protein for administration to animals or humans.

  一种含有溶解在 pH 值为 7.0 至 8.0、用月桂酸钠稳定的合适载体介质中的 IL-2 或 IFN-β 的药物组合物适合用于人或动物的肠外注射。这种制剂的制备方法是，在从转化生物体中回收蛋白质后，将有效量的月桂酸钠加入到 pH 值为 9 至 9.5 的两种蛋白质中，然后将制剂的 pH 值调节到 7.0 至 8.0 之间。因此，本发明提供了月桂酸钠在稳定白细胞介素-2 或干扰素-β 蛋白方面的用途，以便对动物或人类施用。
• Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
  申请人：CETUS ONCOLOGY CORPORATION

  公开号：EP0268110A1

  公开（公告）日：1988-05-25

  Stable pharmaceutical compositions suitable for parenteral administration to animals or humans are prepared comprising a therapeutically effective amount of a recombinant interleukin-2 (IL-2) protein dissolved in an inert carrier medium comprising one or more biocompatible non-ionic polymeric detergents which act as solubilizer/stabilizers for the claimed formulations.

  本发明制备了适用于动物或人体肠外给药的稳定药物组合物，该组合物包括溶解在惰性载体介质中的治疗有效量的重组白细胞介素-2（IL-2）蛋白，惰性载体介质中含有一种或多种生物相容性非离子聚合物去垢剂，这些去垢剂可用作所述制剂的增溶剂/稳定剂。
• Pharmaceutical compositions of recombinant beta-interferon and formulation processes
  申请人：CETUS ONCOLOGY CORPORATION

  公开号：EP0270799A1

  公开（公告）日：1988-06-15

  Stable pharmaceutical compositions suitable for parenteral administration to animals or humans are prepared comprising a therapeutically effective amount of a recombinant IFN-β protein dissolved in an inert carrier medium comprising as solubilizer/­stabilizer(s) one or more biocompatible non-ionic polymeric detergents or a combination of one or more biocompatible non-ionic polymeric detergents with an additional solubilizing and/or stabilizing agent, such as sodium dodecyl sulfate or glycerol. Said compositions are in liquid form or lyophilized.

  适用于动物或人体肠外给药的稳定药物组合物的制备方法是将治疗有效量的重组 IFN-β 蛋白溶解在惰性载体介质中，惰性载体介质的增溶剂/稳定剂包括一种或多种生物相容性非离子聚合物洗涤剂，或一种或多种生物相容性非离子聚合物洗涤剂与十二烷基硫酸钠或甘油等增溶剂和/或稳定剂的组合。所述组合物为液态或冻干状态。

表征谱图